TY - JOUR
T1 - The use of artificial intelligence to identify subjects with a positive FOBT predicted to be non-compliant with both colonoscopy and harbor cancer
AU - Konikoff, Tom
AU - Flugelman, Anath
AU - Comanesther, Doron
AU - Cohen, Arnon Dov
AU - Gingold-Belfer, Rachel
AU - Boltin, Doron
AU - Golan, Maya Aharoni
AU - Eizenstein, Sapir
AU - Dotan, Iris
AU - Perry, Hagit
AU - Levi, Zohar
N1 - Publisher Copyright:
© 2023 Editrice Gastroenterologica Italiana S.r.l.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Background: Subjects with a positive Fecal Occult Blood Test (FOBT) that are non-compliant with colonoscopy are at increased risk for colorectal cancer (CRC). Yet, in clinical practice, many remain non-compliant. Aims: To evaluate whether machine learning models (ML) can identify subjects with a positive FOBT predicted to be both non-compliant with colonoscopy within six months and harbor CRC (defined as the "target population"). Methods: We trained and validated ML models based on extensive administrative and laboratory data about subjects with a positive FOBT between 2011 and 2013 within Clalit Health that were followed for cancer diagnosis up to 2018. Results: Out of 25,219 included subjects, 9,979(39.6%) were non-compliant with colonoscopy, and 202(0.8%) were both non-compliant and harbored cancer. Using ML, we reduced the number of subjects needed to engage from 25,219 to either 971 (3.85%) to identify 25.8%(52/202) of the target population, reducing the number needed to treat (NNT) from 124.8 to 19.4 or to 4,010(15,8%) to identify 55.0%(52/202) of the target population, NNT = 39.7. Conclusion: Machine learning technology may help healthcare organizations to identify subjects with a positive FOBT predicted to be both non-compliant with colonoscopy and harbor cancer from the first day of a positive FOBT with improved efficiency.
AB - Background: Subjects with a positive Fecal Occult Blood Test (FOBT) that are non-compliant with colonoscopy are at increased risk for colorectal cancer (CRC). Yet, in clinical practice, many remain non-compliant. Aims: To evaluate whether machine learning models (ML) can identify subjects with a positive FOBT predicted to be both non-compliant with colonoscopy within six months and harbor CRC (defined as the "target population"). Methods: We trained and validated ML models based on extensive administrative and laboratory data about subjects with a positive FOBT between 2011 and 2013 within Clalit Health that were followed for cancer diagnosis up to 2018. Results: Out of 25,219 included subjects, 9,979(39.6%) were non-compliant with colonoscopy, and 202(0.8%) were both non-compliant and harbored cancer. Using ML, we reduced the number of subjects needed to engage from 25,219 to either 971 (3.85%) to identify 25.8%(52/202) of the target population, reducing the number needed to treat (NNT) from 124.8 to 19.4 or to 4,010(15,8%) to identify 55.0%(52/202) of the target population, NNT = 39.7. Conclusion: Machine learning technology may help healthcare organizations to identify subjects with a positive FOBT predicted to be both non-compliant with colonoscopy and harbor cancer from the first day of a positive FOBT with improved efficiency.
KW - Artificial intelligence
KW - Colorectal cancer
KW - Fecal occult blood test
KW - Machine learning
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=85161025481&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2023.04.027
DO - 10.1016/j.dld.2023.04.027
M3 - Article
C2 - 37286451
AN - SCOPUS:85161025481
SN - 1590-8658
VL - 55
SP - 1253
EP - 1258
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 9
ER -